Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial

OBJECTIVES: Riociguat is approved for pulmonary arterial hypertension and has antiproliferative, anti-inflammatory and antifibrotic effects in animal models of tissue fibrosis. We evaluated the efficacy and safety of riociguat in patients with early diffuse cutaneous systemic sclerosis (dcSSc) at hi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ann Rheum Dis
Hauptverfasser: Khanna, Dinesh, Allanore, Yannick, Denton, Christopher P, Kuwana, Masataka, Matucci-Cerinic, Marco, Pope, Janet E, Atsumi, Tatsuya, Bečvář, Radim, Czirják, László, Hachulla, Eric, Ishii, Tomonori, Ishikawa, Osamu, Johnson, Sindhu R, De Langhe, Ellen, Stagnaro, Chiara, Riccieri, Valeria, Schiopu, Elena, Silver, Richard M, Smith, Vanessa, Steen, Virginia, Stevens, Wendy, Szücs, Gabriella, Truchetet, Marie-Elise, Wosnitza, Melanie, Laapas, Kaisa, de Oliveira Pena, Janethe, Yao, Zhen, Kramer, Frank, Distler, Oliver
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2020
Schlagworte:
Systemic Sclerosis
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213318/
https://ncbi.nlm.nih.gov/pubmed/32299845
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2019-216823
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge